Summary of Key Information:
Reporting Period (Quarter/Year): Not Applicable
Nature of Filing / Announcement: Allotment of equity shares under employee stock option schemes
Audit Opinion:
Not Specified
Key Financial Highlights:
Capital Structure Impact:
- Paid-up share capital increased from ₹438,669,111 to ₹441,044,262
- Increase of ₹2,375,151 (face value ₹1 per share)
- Money realized from option exercise: ₹188,988,302
Corporate Actions:
ESOP Allotment Details:
- Total shares allotted: 2,375,151 equity shares
- Distinctive number range: 438673276 - 441048426
- Shares rank pari passu with existing equity shares
- No lock-in restrictions applicable
Scheme-wise Breakdown:
| Scheme | Exercise Price (₹) | Premium (₹) | Shares Allotted |
| ESOS 2012 | 1.25 | 0.25 | 11,911 |
| ESOS 2016 | 1.25 | 0.25 | 50,478 |
| ESOS 2020 | 1.25 | 0.25 | 1,900 |
| ESOS 2021 | 1.25 | 0.25 | 283,403 |
| ESOS 2024 | 93 | 92 | 27,459 |
| ESOS 2025 | 93 | 92 | 2,000,000 |
Remaining Vested Options (as of July 23, 2026):
- ESOS 2012: 134,120 options
- ESOS 2016: 130,296 options
- ESOS 2020: 190,673 options
- ESOS 2021: 1,857,328 options
- ESOS 2024: Not specified
- ESOS 2025: 4,000,000 options
Lapsed Options (since scheme inception):
- ESOS 2012: 4,991,622 options
- ESOS 2016: 3,295,529 options
- ESOS 2020: 695,618 options
- ESOS 2021: 3,392,765 options
- ESOS 2024: 176,722 options
- ESOS 2025: Not specified
Compliance References:
- Filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Complies with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 updated till January 30, 2026
- Complies with Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
- All schemes are in terms of SEBI regulations
Previous Filings:
- ESOS 2012: Filed October 29, 2024 (BSE: 215083, NSE: 44983)
- ESOS 2016: Filed October 15, 2024 (BSE: 206901, NSE: 44669)
- ESOS 2020: Filed November 04, 2024 (BSE: 215321, NSE: 45064)
- ESOS 2021: Filed July 24, 2024 & October 09, 2024 (BSE: 207104 & 206899, NSE: 42959 & 44578)
- ESOS 2024: Filed October 04, 2024 (BSE: 213273, NSE: 44466)
- ESOS 2025: Filed April 22, 2025 (BSE: 230402, NSE: 48251)
Other Significant Information:
Scheme Objectives:
- Motivate and retain talented employees
- Attract and retain appropriate human talent
- Achieve sustained growth and creation of shareholder value
- Create sense of ownership and participation among employees
- Provide additional deferred rewards to employees
Pricing Formula:
- Exercise price based on fair market value (closing price on stock exchange with highest trading volume)
- Board/Compensation Committee can provide discount or premium, but not below par value
- Maximum exercise period: five years after vesting of last tranche
Additional Notes:
- No variation of terms of options during the year under review
- Diluted EPS disclosure will be submitted with financial results under Regulation 33
- Announcement available on company website: https://investors.ixigo.com/